Nurix Therapeutics (NRIX) Income from Continuing Operations (2019 - 2026)
Nurix Therapeutics (NRIX) reported Income from Continuing Operations of 87174000.0 for Q1 2026, down 54.7% year-over-year from 192429570.43 in Q1 2025, and down 11.45% quarter-over-quarter from 78221000.0 in Q4 2025.
Nurix Therapeutics (NRIX) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Nurix Therapeutics (NRIX) has 8 years of Income from Continuing Operations data on file, last reported at 87174000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 87174000.0, down 54.7% year-over-year; the trailing twelve-month figure through Feb 2026 was 295280000.0 (down 41.69% YoY), and the FY2025 annual result was 264457000.0, down 36.62% from the prior year.
- Income from Continuing Operations eased to 87174000.0 in Q1 2026 per NRIX's latest filing, from 78221000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 24277000.0 in Q2 2023 and troughed at 87174000.0 in Q1 2026.
- A 5-year average of 51147529.41 and a median of 45401000.0 in 2022 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations surged 46.53% in 2023, then slumped 83.49% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 46717000.0 in 2022, then gained by 10.19% to 41956000.0 in 2023, then plunged by 39.55% to 58549000.0 in 2024, then slumped by 33.6% to 78221000.0 in 2025, then fell by 11.45% to 87174000.0 in 2026.
- Business Quant data shows NRIX's Income from Continuing Operations at 87174000.0 in Q1 2026, 78221000.0 in Q4 2025, and 86421000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Nurix Therapeutics | 1.93 Bn | 1.39 Bn | - | -87.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -87.17 Mn |
| Nov 30, 2025 | -78.22 Mn |
| Aug 31, 2025 | -86.42 Mn |
| May 31, 2025 | -43.46 Mn |
| Feb 28, 2025 | -56.35 Mn |
| Nov 30, 2024 | -58.55 Mn |
| Aug 31, 2024 | -48.96 Mn |
| May 31, 2024 | -44.55 Mn |
| Feb 29, 2024 | -41.52 Mn |
| Nov 30, 2023 | -41.96 Mn |
| Aug 31, 2023 | -36.98 Mn |
| May 31, 2023 | -24.28 Mn |
| Feb 28, 2023 | -40.73 Mn |
| Nov 30, 2022 | -46.72 Mn |
| Aug 31, 2022 | -45.71 Mn |
| May 31, 2022 | -45.40 Mn |
| Feb 28, 2022 | -42.53 Mn |
| Nov 30, 2021 | -37.70 Mn |
| Aug 31, 2021 | -28.84 Mn |
| May 31, 2021 | -26.34 Mn |